GlassScriptPhysician profile
Michael Giacoumopoulos
NPI 1972110658
$7,067.57
in general payments reported to CMS, 2019-2025
29 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,076 · 2022: $1,153 · 2023: $1,638 · 2024: $1,931 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,753 · Education: $86.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,752.53 |
| Education | $86.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,740.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $904.79 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $880.28 | 2021-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $681.46 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $541.75 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.05 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $212.04 | 2021-2025 | Capvaxive, Gardasil 9, Verquvo |
| Astellas Pharma US INC | $182.27 | 2021-2025 | Veozah |
| Pfizer INC. | $176.85 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.86 | 2022-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $147.64 | 2022-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $111.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $109.59 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $85.22 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $74.62 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $70.42 | 2023-2025 | Sunosi, Auvelity |
| Janssen Pharmaceuticals, INC | $63.06 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $59.39 | 2021-2024 | Nexletol |
| Phathom Pharmaceuticals, INC. | $56.56 | 2024-2025 | Voquezna |
| Almatica Pharma LLC | $55.23 | 2022-2024 | Loreev Xr |
| Horizon Therapeutics Plc | $48.57 | 2021-2022 | |
| Amarin Pharma, INC. | $44.99 | 2022-2023 | |
| Ardelyx, INC. | $40.81 | 2024-2025 | Ibsrela |
| Phadia US INC. | $30.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.54 | 2023 | Eliquis |
| Idorsia Pharmaceuticals US INC | $23.00 | 2023 | Quviviq |
| Azurity Pharmaceuticals, INC. | $18.18 | 2024 | Edarbyclor |
| Novartis Pharmaceuticals Corporation | $17.63 | 2021 | |
| Gilead Sciences, INC. | $16.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Giacoumopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.